MS Speaks

Multiple Sclerosis => TREATMENTS => TYSABRI (natalizumab) => Topic started by: agate on April 27, 2018, 02:23:48 pm

Title: (AAN) PML risk cut by extending Tysabri dosing interval
Post by: agate on April 27, 2018, 02:23:48 pm
From Multiple Sclerosis News Today, April 23, 2018--"#AAN2018: PML Risk Cut by Extending Tysabri Dosing Interval":


https://multiplesclerosisnewstoday.com/2018/04/27/aan2018-pml-risk-cut-by-extending-tysabri-dosing-interval/
Title: Reducing PML risk with natalizumab
Post by: agate on May 20, 2018, 03:42:31 pm
Another article about this in MedPage Today, May 10, 2018--"Reducing PML risk with natalizumab":


https://www.medpagetoday.com/meetingcoverage/aanposterrounds/72808?xid=nl_mpt_DHE_2018-05-11&eun=g345846d0r&pos=0&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202018-05-11&utm_term=Daily%20Headlines%20-%20Active%20User%20-%20180%20days
Title: Biogen starts Phase 3b trial to evaluate Tysabri extended dosing interval
Post by: agate on January 08, 2019, 03:34:20 pm
From Medical News Today, January 7, 2019--"Biogen starts Phase 3B trial to evaluate Tysabri extended interval dosing for RRMS patients." The dosing regimen being studied would involve receiving Tysabri every 6 weeks instead of every 4 weeks.


https://multiplesclerosisnewstoday.com/2019/01/07/phase-3b-trial-tysabri-extended-interval-dosing-rrms/
Title: (Abst.) Pharmacodynamics of natalizumab extended interval dosing in MS
Post by: agate on February 06, 2020, 08:11:09 pm

These researchers have found that extended interval dosing of Tysabri (every 5-8 weeks) doesn't reduce the effectiveness of the drug.

From PubMed, February 6, 2020--"Pharmacodynamics of natalizumab extended interval dosing in MS":


https://www.ncbi.nlm.nih.gov/pubmed/32019876
Title: Biogen's results from Phase 3b study comparing Tysabri dosing every 4 weeks with every 6 weeks
Post by: agate on August 02, 2021, 06:25:05 pm

Biogen's study comparing Tysabri dosing every 4 weeks with dosing every 6 weeks apparently resulted in an 88% reduction in the risk of contracting PML with the less-frequent dosing:

From Pipeline Review (August 2, 2021), "Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis":


https://bit.ly/37edx03




Title: No significant difference in patient-reported outcomes w/Tysabri every 6 weeks
Post by: agate on June 05, 2022, 04:37:54 pm
More on this from Neurologylive.com (June 4, 2022), discussing a study presented at the annual CMSC meeting June 1-4, "No Significant Difference in Patient-Reported Outcomes with Natalizumab When Administered Every 6 Weeks":


https://bit.ly/3MmDeNO